Published on Web 11/04/2010
Promising General Solution to the Problem of Ligating
Peptides and Glycopeptides
Ping Wang† and Samuel J. Danishefsky*,†,‡
Laboratory for Bioorganic Chemistry, Sloan-Kettering Institute for Cancer Research, 1275 York
AVenue, New York, New York 10065, and Department of Chemistry, Columbia UniVersity,
HaVemeyer Hall, 3000 Broadway, New York, New York 10027, United States
Received September 19, 2010; E-mail: s-danishefsky@ski.mskcc.org
Abstract: Our global goal is that of synthesizing complex polypeptides and glycopeptides in homogeneous
form. Chemistry-derived access to homogeneous biologics could well have useful consequences in the
discovery of drugs and vaccines. The key finding in this study is that thio acids can become highly competent
acyl donors following even trace levels of oxidative activation, thereby undergoing amide bond formation
upon reaction with N-terminal peptides. Though our data set does not establish the specific mechanism of
this reaction, a framework to account for the fact that minute levels of oxidation actuate amide bond formation
with high turnover is offered. An apparently general coupling of thio acids (including complex peptide thio
acids with N-termini of complex peptides) has thus been realized. These ligations are conducted with minimal
R-epimerization in the C-terminal group and allow for the coupling of N-terminal and C-terminal glycopeptides
en route to homogeneous glycoproteins.
Introduction
the accessibility of a class of highly complex biologics to
chemical synthesis.5
There is a sharp division in current modalities of development
between small-molecule-based drugs and large-molecule agents,
which are often referred to as “biologics”. Small-molecule
prospects are seen to arise from “chemistry”. By contrast,
biologics (cf. vaccines, antibodies, enzymes, and factors) are
perceived to be derivable from strictly biological means. It is
our view that recent advances in the scope and depth of organic
chemistry raise the possibility that chemical synthesis could well
play a valuable role in fashioning biologic-level candidate
structures.1 For such a goal to be feasible in the molecular space
of biologics, complex issues associated with the assembly of
key biolevel repeating building blocks must be mastered.
Biologically active glycopeptides and glycoproteins are of
particular interest to our laboratory.2 A formidable challenge
in reaching such compounds via synthesis is that of joining and
managing two differing biolevel domains (polysaccharides3
and polypeptides), each with their own chemical personalities
and vulnerabilities. Since target glycopeptides or glycoproteins
tend to arise in nature as horrific mixtures of glycoforms,
chemical synthesis might well provide the best prospect for
reaching and evaluating homogeneous glycopeptides for
structure-activity relationship (SAR) studies. We have de-
scribed strategies and enabling methodologies for assembling
complex oligosaccharides with high levels of convergence and
stereocontrol.4 These advances have, for instance, been used in
the building of fully synthetic vaccines, thereby establishing
A massive advance in the capacity to synthesize homogeneous
polypeptides, and even modestly sized proteins, arose from the
seminal discovery of native chemical ligation (NCL) by Kent
and colleagues.6 In NCL, a C-terminal acyl donor is initially
joined to the SH group of an N-terminal cysteine site. Following
S f N acyl transfer, a peptide bond is fashioned (Figure 1a).
Our laboratory has extended the inherent logic of NCL by
exploiting metal-free chemospecific dethiolation of SH groups,
thereby allowing Ala ligation to become a practical option via
an N-terminal Cys.7 By installing thiol groups into otherwise
proteogenic amino acids through chemical synthesis, the elegant
concept of NCL has been extended to enable ligations at
N-terminal Phe, Val, Thr, and Leu sites.8 Helpful as such
advances have been, there is still a huge unmet need for a broadly
based method to enable the ligation of peptides, including glyco-
(4) For reviews, see: (a) Seeberger, P. H.; Bilodeau, M. T.; Danishefsky,
S. J. Aldrichimica Acta 1997, 30, 75–92. (b) Zhu, J.; Warren, J. D.;
Danishefsky, S. J. Expert ReV. Vaccines 2009, 8, 1399–1413.
(5) For two particularly interesting approaches to amide bond formation from
nonobvious coupling partners, see: (a) Carrillo, N.; Davalos, E. A.; Russak,
J. A.; Bode, J. W. J. Am. Chem. Soc. 2006, 128, 1452–1453. (b) Shen,
B.; Makley, D. M.; Johnston, J. N. Nature 2010, 465, 1027–1033.
(6) (a) Dawson, P. E.; Muir, T. W.; Clark-Lewis, I.; Kent, S. B. H. Science
1994, 266, 776–779. (b) Dawson, P. E.; Churchill, M. J.; Ghadiri,
M. R.; Kent, S. B. H. J. Am. Chem. Soc. 1997, 119, 4325–4329.
(7) Wan, Q.; Danishefsky, S. J. Angew. Chem., Int. Ed. 2007, 46, 9248–
9252.
† Sloan-Kettering Institute for Cancer Research.
‡ Columbia University.
(8) (a) Yang, L.; Dawson, P. E. J. Am. Chem. Soc. 2001, 123, 526–533.
(b) Crich, D.; Banerjee, A. J. Am. Chem. Soc. 2007, 129, 10064–
10065. (c) Haase, C.; Rohde, H.; Seitz, O. Angew. Chem., Int. Ed.
2008, 47, 6807–6810. (d) Chen, J.; Wan, Q.; Yuan, Y.; Zhu, J.;
Danishefsky, S. J. Angew. Chem., Int. Ed. 2008, 47, 8521–8524. (e)
Chen, J.; Wang, P.; Zhu, J.; Wan, Q.; Danishefsky, S. J. Tetrahedron
2010, 66, 2277–2283. (f) Harpaz, Z.; Siman, P.; Kumar, K. S. A.;
Brik, A. ChemBioChem 2010, 11, 1232–1235.
(1) Nagorny, P.; Fasching, B.; Li, X.; Chen, G.; Aussedat, B.; Danishefsky,
S. J. J. Am. Chem. Soc. 2009, 131, 5792–5799.
(2) Tan, Z.; Shang, S.; Halkina, T.; Yuan, Y.; Danishefsky, S. J. J. Am.
Chem. Soc. 2009, 131, 5424–5431.
(3) Danishefsky, S. J.; Bilodeau, M. T. Angew. Chem., Int. Ed. Engl. 1996,
35, 1830–1419.
9
10.1021/ja1084628 2010 American Chemical Society
J. AM. CHEM. SOC. 2010, 132, 17045–17051 17045